TABLE 1.
Demographic and Baseline Characteristics of Patients with mCRPC (n = 138)
| Characteristic | All patients | 177Lu-PSMA I&T group | 177Lu-PSMA-617 group |
|---|---|---|---|
| Number of patients | 138 | 51 | 87 |
| Age (y) | 70 ± 9 (46–90) | 71 ± 9 (46–87) | 69 ± 9 (50–90) |
| ISUP grading | |||
| Group 1 | 7 (5.1%) | 2 (3.9%) | 5 (5.7%) |
| Group 2 | 20 (14.5%) | 3 (5.9%) | 17 (19.5%) |
| Group 3 | 21 (15.2%) | 10 (19.6%) | 11 (12.6%) |
| Group 4 | 26 (18.8%) | 6 (11.8%) | 20 (23.0%) |
| Group 5 | 39 (28.3%) | 18 (35.3%) | 21 (24.1%) |
| NA | 25 (18.1%) | 12 (23.5%) | 13 (14.9%) |
| PSA level (ng/mL) | 216.5 ± 538.7 | 90.6 ± 158.7 | 283.3 ± 648.2 |
| Metastases | |||
| Lymph nodes | 109 (79.0%) | 38 (74.5%) | 71 (81.6%) |
| Bone | 108 (78.2%) | 39 (76.5%) | 69 (79.3%) |
| Bone marrow | 11 (8.0%) | 2 (3.9%) | 9 (10.3%) |
| Lung | 15 (10.9%) | 6 (11.8%) | 9 (10.3%) |
| Liver | 12 (8.7%) | 4 (7.8%) | 8 (9.2%) |
| Other | 36 (26.1%) | 10 (19.6%) | 26 (29.9%) |
| Injected activity (GBq) | 6.4 ± 1.0 (3.4–9.0) | 6.1 ± 1.0 (3.4–7.6) | 6.5 ± 1.1 (3.5–9.0) |
ISUP = International Society of Urological Pathology; NA = not available; PSA = prostate-specific antigen.
Qualitative data are number and percentage; continuous data are mean and range.